Pinnacle Associates’s Acumen Pharmaceuticals ABOS Stock Holding History

Pinnacle Associates’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48.1K	Hold	18,020	–	–	﹤0.01%	961
2026 Q1	$42.5K	Hold	18,020	–	–	﹤0.01%	950
2025 Q4	$38K	Hold	18,020	–	–	﹤0.01%	926
2025 Q3	$30.8K	Hold	18,020	–	–	﹤0.01%	861
2025 Q2	$20.9K	Hold	18,020	–	–	﹤0.01%	843
2025 Q1	$19.8K	Hold	18,020	–	–	﹤0.01%	820
2024 Q4	$31K	Buy	+18,020	New	+$43.4K	﹤0.01%	830
2024 Q3	–	Sell	-18,020	Closed	-$43.6K	–	801
2024 Q2	$43.6K	Hold	18,020	–	–	﹤0.01%	805
2024 Q1	$73K	Buy	+18,020	New	+$67.9K	﹤0.01%	820
2023 Q4	–	Sell	-18,020	Closed	-$74.8K	–	819
2023 Q3	$74.8K	Hold	18,020	–	–	﹤0.01%	793
2023 Q2	$86.7K	Buy	+18,020	New	+$86.3K	﹤0.01%	793

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Pinnacle Associates's ABOS Position: Q2 2026 in Review

Pinnacle Associates held its Acumen Pharmaceuticals (ABOS) position steady in Q2 2026 at 18,020 shares worth $48.1K. The position accounts for ﹤0.01% of the portfolio, ranked #961.

Pinnacle Associates first reported a position in ABOS in Q2 2023 and has held it in 11 quarters since. The position peaked at $86.7K in Q2 2023. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

Pinnacle Associates held 18,020 shares of Acumen Pharmaceuticals worth $48.1K as of Q2 2026.
Pinnacle Associates left its Acumen Pharmaceuticals share count unchanged in Q2 2026.
Acumen Pharmaceuticals made up ﹤0.01% of Pinnacle Associates's portfolio in Q2 2026, its #961 holding.
Pinnacle Associates first reported a position in Acumen Pharmaceuticals in Q2 2023 and has held it in 11 quarters since.
Pinnacle Associates's Acumen Pharmaceuticals position peaked at $86.7K in Q2 2023.
96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Pinnacle Associates's 13F filing for Q2 2026, filed 3 Aug 2026.